Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5983_Библиотеки_им_академика_М_И_Перельмана.pdf
328
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
J. Biomed. Mater. Res.
B Appl. Biomater. 2017, 105,
Engineering Mineralized and Load
Bearing Tissues, Advances in Experimental Medicine and Biology; Bertassoni, L. E.,
Drug Discov. Today 2019, 24,
Adv. Healthc.
Mater. 2017,
Int. J. Oral Maxillofac. Surg. 2017,
46,
Nanomaterials and Neoplasms
Publishing, 2021.
Int J Recent Sci Res 2018, 9, 23899–903.
Maxillofac. Plast. Reconstr. Surg. 2015, 37,
Orv. Hetil. 2012, 153,
oh.2012.29306
RSC Adv. 2019,
9,
Biomaterials
2016, 83,
Cell Encapsulation in Alginate Microbeads in Macroporous Calcium Phosphate Cement
Acta Biomater. 2012, 8,
actbio.2012.05.016
Woodhead Publishing, 2018.
Nanomaterials 2021,
11,
Bioceramics System for Biomedical Application
329
Cancer Cells. J. Mater. Chem. 2009, 19,
Mater. Today Proc., 3rd International Conference on Materials Engineering & Science
2021, 42,
V allet-Regí, M. Nanostructured Mesoporous Silica Matrices in Nanomedicine. J. Intern. Med.
2010, 267,
J. Chem. Soc. Dalton Trans. 2001,
J. Biomed. Nanotechnol.
2008, 4,
Prog. Solid State Chem. 2004, 32,
progsolidstchem.2004.07.001
Calbet, J. M. Phosphorous-doped MCM-41 as Bioactive Material. Solid State Sci. 2005, 7,
Nanoceramics in Clinical Use: From Materials to
Applications
Drug Delivery System. Chem. Mater. 2001a, 13,
cm0011559
Drug Delivery System. Chem. Mater. 2001b, 13,
cm0011559
Silica Based Ordered Mesoporous Materials: Medical Applications. J. Mater. Chem. 2006,
16,
Materials
2018, 11,
Amoxicillin. Solid State Ion2004, 172,
Bio-Glasses
Int. J. Oral Maxillofac.
Implants 2006, 21, 575–580.
Case
Rep. 2013, 2013,
ACS Appl. Mater. Interfaces 2015, 7, 24075–
330
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
Incorporation. Chem. Mater. 2004, 16,
and Renal Clearance. Small 2011, 7,
Braz. Oral Res. 2006, 20,
Ceram. Int. 2019, 45,
Acta Biomater.
2011, 7,
Filling Materials: A Histologic Study in Dogs. J. Oral Maxillofac. Surg. 2012, 70, 2041–
ACS
Nano. 2010, 4,
Cell Biochem. Biophys. 2015, 72,
J. Am. Chem. Soc. 2013, 135,
Sci. Eng. C 2020, 108,
msec.2019.110479
Materials. Nat. Mater. 2015, 14,
CRC Press, 1995.
Head
Neck 2010, 32,
Capacity, Osteostimulation and Antibacterial Activity. Biomaterials 2013, 34, 422–433.
Bioceramics System for Biomedical Application
331
Ceram. Int. 2015, 41,
J. Controlled Release 2004, 98,
J. Biomed. Mater. Res. B Appl. Biomater. 2015, 103,
J. Bioact.
Compat. Polym. 2013a, 28,
Applications. Nanomed. 2013b, 8,
Acta Biomater. 2015, 12,
actbio.2014.10.021
Bull. Chem. Soc.
Jpn. 1990, 63,
Drug Delivery. Chem. Mater. 2005, 17,
J. Alloys Compd. 2018, 743,
J. Mol. Catal. B Enzym. 2001, 15, 81–92.
Bone
2009, 44,
Mater. Res. Bull. 2005,
40,
Materials MCM-41 and MCM-50. J. Phys. Chem. B 1997, 101,
Engineering. Mater. Sci. Eng. C, Next Gen. Biomater. 2007, 27,
332
Advances in Pharmaceutical Technology for Drug Delivery Systems (PTDDS), Volume 2
Ceram. Int. 2013, 39,
Pores. Science 1998, 279,
Dental Pulp Stem Cells. Mol. Biol. Rep. 2012, 39,
Index
A
Administrative routes
intramuscular (IM), 10–11
intravenous, 9–10
nasal administration, 15–16
ocular delivery, 13–14
oral delivery, 12–13
pulmonary route, 14–15
subcutaneous, 11
transdermal, 11–12
transmucosal drug delivery, 16
Albumin, 116–119
Alginates, 114–115, 205–206
Antihypertensive, 261–262
Antimicrobial, 262–263
B
Biocarriers, 103–104
carbohydrates, 104–105
exosomes, 116–131
protein, 115–116
Bioceramics system
biomedical application, 291, 294
biodegradability, 296–297
doped, 310–312
drug delivery, 308–310
mechanical, 294–295
orthopedic, 298–304
osteoconductivity, 297–298
porosity, 295–296
Brain targeting, 22, 101
alginates, 114–115
biocarriers, 103–104
carbohydrates, 104–105
exosomes, 116–131
protein, 115–116
carbohydrates, 114
chitosan, 105–111
hyaluronic acid, 111–114
cyclodextrin, 115
dextran, 115
protein
albumin, 116–119
casein, 125–126
collagen, 119–121
gelatin, 121–123
Breast cancer
and cardiotoxicity, applications, 35
advances, 51–56
nutritional, 46–51
physical exercise, 42–46
C
Cancer diagnosis, 82–88
Cancer therapy, 257–258
Carbohydrates
chitosan, 105–111
hyaluronic acid, 111–114
Cardiotoxicity
breast cancer, 35
advances, 51–56
nutritional, 46–51
physical exercise, 42–46
Casein, 125–126
Cellulose, 205
Charge-inducing molecules, 6
Chitosan, 206–207
Cholesterol, 6
Coating, 225
Critical packing parameter (CPP), 7–8
Cyclodextrin, 115
D
3D printed devices, 197
common polymers
334 Index
alginate, 205–206
cellulose, 205
chitosan, 206–207
synthetic, 207
dosage, 211
capsule, 220
microneedles, 218–220
tablets, 217–218
extrusion
semisolid, 202–203
blends, 222–223
coating, 225
cross-linking, 224–225
matrix, 222
multicompartment, 225–226
pores, 224
extrusion, 201
selective laser, 204
stereolithography, 203
synthetic
eudragit, 210–211
gelatin methacrylate (GelMA), 210
polycaprolactone, 207–208
polyethylene glycol, 208–209
polylactic acid, 208
polyvinyl alcohol, 209
polyvinylpyrrolidone (PVP), 209–210
Dextran, 115
Diagnostic imaging, 20–21
Drug delivery, 308–310
E
Electrospinning, 70–71, 250
biomaterials, 73
parameters, 71–73
Electrospun technology, 67
biomaterials
composite, 75
natural, 73–74
synthetic, 74–75
cancer diagnosis, 82–88
electrospinning, 70–71
biomaterials, 73
parameters, 71–73
blending, 76–77
coaxial, 78
emulsion, 77–78
tissue engineering, 79
hard, 79–81
Eudragit, 210–211
Extrusion, 201
F
Fused deposition, 201–202
G
Gelatin, 121–123
Gelatin methacrylate (GelMA), 210
Gene delivery, 175
carbon-based, 186–188
dendrimer, 184–185
intracellular, 177–178
metallic, 189–191
polymer, 180–184
preclinical studies, 179–180, 180
properties, 178–179
silica, 188–189
solid–lipid nanoparticles (LNPs), 185–186
Graphene quantum dots (GQd)
bottom–up, 146–147
Graphene-based system, 139
applications
bioimaging, 159–161
drug delivery, 150–157
gene, 157–159
photothermal, 161–164
tissue engineering, 164–167
cytocompatibility, 147–150
graphene quantum dots (GQd)
bottom–up, 146–147
Index 335
synthesis, 141
GQd, 145
graphene, 141–143
reduced graphene oxide (rGO), 143–145
H
Hyaluronic acid, 111–114
Hydrophilic-lipophilic balance (HLB), 6
I
Intramuscular (IM), 10–11
M
N
application, 259–260, 264–265
antihypertensive, 261–262
antimicrobial, 262–263
cosmetics, 258
parameters, 247
electrical, 248–249
molecular, 248
polymer, 248
temperature, 249
voltage, 249
preparation
applications, 253–254
cancer therapy, 257–258
electrospinning, 250
miscellaneous, 258
phase separation, 251–252
synthesis, 253
tissue engineering, 256–257
blending, 76–77
coaxial, 78
emulsion, 77–78
Nanotechnology
in gene delivery, 175
carbon-based, 186–188
dendrimer, 184–185
intracellular, 177–178
metallic, 189–191
polymer, 180–184
preclinical studies, 179–180, 180
properties, 178–179
silica, 188–189
solid–lipid nanoparticles (LNPs),
185–186
273
engineering, 280–284
nanotechnology, 278–280
tissue, 275–278
Nasal administration, 15–16
Niosomes
administrative routes
intramuscular (IM), 10–11
intravenous, 9–10
nasal administration, 15–16
ocular delivery, 13–14
oral delivery, 12–13
pulmonary route, 14–15
subcutaneous, 11
transdermal, 11–12
transmucosal drug delivery, 16
advantages, 3–4
biomedical applications
brain targeting, 22
diagnostic imaging, 20–21
nonviral gene delivery, 24–25
targeted drug delivery, 22–23
vaccine delivery, 21–22
components
charge-inducing molecules, 6
cholesterol, 6
hydrophilic-lipophilic balance (HLB), 6
drug delivery, 2
critical packing parameter (CPP), 7–8
336 Index
HLB value, 7
phase transition temperature, 8–9
structure, 4
therapeutics
anticancer drugs, 17–18
clinical trial, 19–20
hemoglobin, 19
natural products, 18–19
protein and peptide, 16–17
Nonviral gene delivery, 24–25
O
Ocular delivery, 13–14
Oral delivery, 12–13
Osteoconductivity, 297–298
P
Phase separation, 251–252
Phase transition temperature, 8–9
Polyethylene glycol, 208–209
Polylactic acid, 208
Polyvinyl alcohol, 209
Polyvinylpyrrolidone (PVP), 209–210
Porosity, 295–296
Protein
albumin, 116–119
casein, 125–126
collagen, 119–121
gelatin, 121–123
Pulmonary route, 14–15
R
Reduced graphene oxide (rGO), 143–145
S
Selective laser, 204
Semisolid, 202–203
Solid–lipid nanoparticles (LNPs), 185–186
Stereolithography, 203
T
anticancer drugs, 17–18
clinical trial, 19–20
hemoglobin, 19
natural products, 18–19
protein and peptide, 16–17
hard, 79–81
V
Vaccine delivery, 21–22
W
Wound dressing, 255–256
Z